NCT04450173 - Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 24, 2021

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions

Ann Arbor Stage II Follicular LymphomaAnn Arbor Stage III Follicular LymphomaAnn Arbor Stage IV Follicular LymphomaGrade 1 Follicular LymphomaGrade 2 Follicular LymphomaGrade 3a Follicular Lymphoma

Interventions

DRUG

Ibrutinib

Given PO

BIOLOGICAL

Obinutuzumab

Given IV

DRUG

Venetoclax

Given PO

Trial Locations (4)

90095

NOT_YET_RECRUITING

University of California, Los Angeles, Los Angeles

92037

RECRUITING

University of California, San Diego, San Diego

93701

RECRUITING

University of California, San Francisco (UCSF) Fresno, Fresno

95817

RECRUITING

University of California Davis Comprehensive Cancer Center, Sacramento